Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $3.01 to $3.35
• 50-Day Range: $3.05 to $4.56
• 52-Week Range: $1.93 to $10.16
• Volume: 12,739 shs
• Average Volume: 277,435 shs
• Market Capitalization: $8.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed this year?

Biomerica's stock was trading at $2.4008 at the start of the year. Since then, BMRA shares have increased by 32.9% and is now trading at $3.19.
View the best growth stocks for 2025 here.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) posted its quarterly earnings results on Monday, April, 14th. The company reported ($0.48) EPS for the quarter. The company had revenue of $1.12 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 90.19% and a negative net margin of 100.52%.

When did Biomerica's stock split?

Biomerica's stock reverse split on the morning of Monday, April 21st 2025. The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Who are Biomerica's major shareholders?

Top institutional shareholders of Biomerica include Bulltick Wealth Management LLC (5.39%), Granahan Investment Management LLC (3.46%) and Simplex Trading LLC. Insiders that own company stock include Zackary S Irani, Allen Barbieri and Catherine Coste.
View institutional ownership trends.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 4/14/2025
• Today: 6/05/2025
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BMRA
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 645-2111
• Fax: 949-553-1231
• Employees: 60
• Year Founded: 1971

Profitability

• EPS (Most Recent Fiscal Year): ($2.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.98 million
• Net Margins: -100.52%
• Pretax Margin: -100.31%
• Return on Equity: -90.19%
• Return on Assets: -64.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.17
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $5.68 million
• Price / Sales: 1.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 8.18

Miscellaneous

• Outstanding Shares: 2,546,000
• Free Float: 15,586,000
• Market Cap: $8.12 million
• Optionable: Optionable
• Beta: 0.37